Showing results (41-50 of 102) with videos related to
Sort By:
Pageof 11
Journal of Neurology|September 26, 2006
Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's diseaseKathy Dujardin, David Devos, Stéphane Duhem, et al.Plos One|October 23, 2010
Platelet serotonin level predicts survival in amyotrophic lateral sclerosisLuc Dupuis, Odile Spreux-Varoquaux, Gilbert Bensimon, et al.Dementia and Geriatric Cognitive Disorders|March 16, 2005
Pharmacology of Alzheimer's disease: appraisal and prospectsFrançois Sellal, André Nieoullon, Géraldine Michel, et al.Therapie|June 23, 2005
[Pharmacology of Alzheimer's disease: where do we go from here?]François Sellal, André Nieoullon, Géraldine Michel, et al.Archives of Neurology|June 15, 2011
Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosisHussein Daoud, Véronique Belzil, Sandra Martins, et al.Journal of Neurology|January 20, 2012
Improving survival in a large French ALS center cohortPaul H Gordon, François Salachas, Gaelle Bruneteau, et al.Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement|October 26, 2018
Emotional feeling in patients suffering from amyotrophic lateral sclerosisJohanna Unglik, Catherine Bungener, Daniel Delgadillo, et al.Fundamental & Clinical Pharmacology|May 19, 2011
A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's diseaseOlivier Rascol, Joaquim Ferreira, Laurence Nègre-Pages, et al.Brain : a Journal of Neurology|June 26, 2010
Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsyRichard G Brown, Lucette Lacomblez, Bernard G Landwehrmeyer, et al.Parkinsonism & Related Disorders|July 16, 2019
Are PSP patients included in clinical trials representative of the general PSP population?Louise-Laure Mariani, Raquel Guimarães-Costa, David Grabli, et al.Pageof 11